Halia Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today ...

Approved JAK inhibitors such as ruxolitinib and fedratinib target the JH1 kinase domain, offering symptomatic relief but lacking selectivity for the mutant form. This non-selective inhibition disrupts ...

Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with ...

The Novel Allosteric NEK7 Inhibitor Ofirnoflast (HT-6184) Demonstrates Robust and Sustained Hematologic Response in Subjects with IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome ...

HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for ...

Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual ...

Chemomab Therapeutics (CMMB) announced that abstracts that highlight new clinical data from the nebokitug Phase 2 SPRING trial in primary ...

Immunocore Holdings plc (Nasdaq: IMCR) ('Immunocore” or the 'Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically ...

SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery ...

The draft curriculum, which has been submitted to the NCERT for review, provides a structure for schools to introduce ...

Another quiet sign of growth is spending in ways that buy back your time and attention. Paying for public transit or a ...